Swiss National Bank Reduces Stock Holdings in QIAGEN N.V. (NYSE:QGEN)

Swiss National Bank decreased its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 5.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 618,909 shares of the company's stock after selling 32,738 shares during the quarter. Swiss National Bank owned about 0.28% of QIAGEN worth $24,535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. ANTIPODES PARTNERS Ltd bought a new stake in QIAGEN during the 1st quarter valued at $94,000. Tower Research Capital LLC TRC raised its holdings in QIAGEN by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after acquiring an additional 2,204 shares during the period. GAMMA Investing LLC raised its holdings in QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the period. Federated Hermes Inc. bought a new stake in QIAGEN during the 1st quarter valued at $150,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in QIAGEN during the 4th quarter valued at $202,000. Institutional investors own 70.00% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Wall Street Zen cut shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday. Barclays initiated coverage on shares of QIAGEN in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. Cowen reaffirmed a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Bank of America upped their price target on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Finally, UBS Group upped their price target on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, QIAGEN presently has a consensus rating of "Hold" and a consensus target price of $49.69.

QIAGEN Stock Up 2.0%

QGEN opened at $48.98 on Wednesday. The stock has a market cap of $10.89 billion, a PE ratio of 28.94, a P/E/G ratio of 2.45 and a beta of 0.64. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The business's fifty day simple moving average is $48.15 and its 200 day simple moving average is $43.60.

QIAGEN (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. The business had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%. The firm's revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.55 earnings per share. As a group, research analysts expect that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

QIAGEN Dividend Announcement

The company also recently announced a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were paid a $0.25 dividend. This represents a yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's dividend payout ratio is currently 14.79%.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QIAGEN N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.